Clinical Trial Detail

NCT ID NCT02939300
Title Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.